“Rising Prevalence of Rare and Chronic Diseases”
- A major driving force behind the blood plasma & plasma derived medicinal products market is the increasing prevalence of rare and chronic diseases globally, fueled by advancements in diagnostic technologies and heightened awareness among healthcare providers and patients
- For instance, in April 2025, CDC data revealed that 76.4% of U.S. adults had at least one chronic condition, and 51.4% had multiple conditions. This rising trend—also observed among younger adults—has intensified the demand for lifelong care, particularly for conditions like hemophilia, primary immunodeficiency diseases, and von Willebrand disease
- Plasma-derived therapies such as immunoglobulins, coagulation factors, and albumin are critical for managing these lifelong conditions. Patients with Primary Immunodeficiency rely on IVIG for immune support, while hemophilia patients require regular clotting factor infusions to prevent bleeding episodes
- The global aging population further drives this trend, with older adults increasingly affected by conditions like liver cirrhosis, multiple myeloma, and inflammatory diseases, all of which necessitate plasma-derived interventions
- In March 2025, research published in PMC highlighted the immense global burden of rare diseases, especially among pediatric populations. Despite progress in genomic medicine and orphan drug development, delays in diagnosis and limited treatment options persist, underscoring the need for multidisciplinary and sustained care
- The growing demand for safe, effective, and high-quality plasma-derived therapies is a pivotal factor driving the blood plasma & plasma derived medicinal products market, as these products play a crucial role in managing lifelong diseases and addressing unmet Medicinal needs in Europe
